EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieVergleichsstudieOpen Access

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

Komal L Jhaveri, Patrick Neven, Monica Lis Casalnuovo, Sung-Bae Kim, Eriko Tokunaga, Philippe Aftimos, Cristina Saura, Joyce O'Shaughnessy, Nadia Harbeck, Lisa A Carey iD, Giuseppe Curigliano iD, Antonio Llombart-Cussac und 18 weitere

New England Journal of Medicine · 27.03.2025 · 392 (12) · 1189-1202

DOI: 10.1056/nejmoa2410858 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 27.03.2025. Verfasst von Komal L Jhaveri und 29 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York. Hauptthemen laut MEDLINE: Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Breast Neoplasms. Die Arbeit wurde bisher 232-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminopyridinesAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesBreast NeoplasmsBenzopyransBreast Neoplasms, MaleAdultAgedAged, 80 and overFemaleHumansMiddle AgedEstrogen Receptor alphaMutationProgression-Free SurvivalErb-b2 Receptor Tyrosine KinasesFulvestrantMaleTreatment OutcomeAndrostadienes

Substanzen

AminopyridinesBenzimidazolesEstrogen Receptor alphaBenzopyransErb-b2 Receptor Tyrosine KinasesFulvestrantAndrostadienesabemaciclibESR1 protein, humanImlunestrant

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York.
  • University Hospitals Leuven, Leuven, Belgium.
  • Hospital María Curie, Buenos Aires.
  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Brussels.

ORCID-Profile: Lisa A Carey, Giuseppe Curigliano, Joohyuk Sohn, François-Clément Bidard

Förderung

  • NCI NIH HHS
  • Eli Lilly and Company

Zitieren

APA

Jhaveri, K. L., Neven, P., Casalnuovo, M. L., Kim, S. B., Tokunaga, E., Aftimos, P., Saura, C., O'Shaughnessy, J., Harbeck, N., Carey, L. A., Curigliano, G., Llombart-Cussac, A., Lim, E., García Tinoco, M. L., Sohn, J., Mattar, A., Zhang, Q., Huang, C. S., Hung, C. C., …, & EMBER-3 Study Group (2025). Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. New England Journal of Medicine, 392(12), 1189-1202. https://doi.org/10.1056/nejmoa2410858

Vancouver

Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, et al. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. New England Journal of Medicine. 2025;392(12):1189-1202. doi:10.1056/nejmoa2410858

BibTeX
@article{Jhaveri2025,
  author = {Jhaveri, Komal L and Neven, Patrick and Casalnuovo, Monica Lis and Kim, Sung-Bae and Tokunaga, Eriko and Aftimos, Philippe and Saura, Cristina and O'Shaughnessy, Joyce and Harbeck, Nadia and Carey, Lisa A and Curigliano, Giuseppe and Llombart-Cussac, Antonio and Lim, Elgene and García Tinoco, María de la Luz and Sohn, Joohyuk and Mattar, André and Zhang, Qingyuan and Huang, Chiun-Sheng and Hung, Chih-Chiang and Martinez Rodriguez, Jorge Luis and Ruíz Borrego, Manuel and Nakamura, Rikiya and Pradhan, Kamnesh R and Cramer von Laue, Christoph and Barrett, Emily and Cao, Shanshan and Wang, Xuejing Aimee and Smyth, Lillian M and Bidard, François-Clément and EMBER-3 Study Group, EMBER-3 Study Group},
  title = {Imlunestrant with or without Abemaciclib in Advanced Breast Cancer},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {12},
  pages = {1189--1202},
  doi = {10.1056/nejmoa2410858}
}
Kostenlos starten →